Stevanato Group S.p.A.: Stevanato Group Reports First Quarte

- Reiterates Full Year 2023 Guidance - Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology

Related Keywords

United States , United Kingdom , Indiana , Italy , Franco Stevanato , Franco Moro , Development Expenses , Stevanato Group , Exchange Commission , Company Investor Relations , Solutions Segment , Full Year , Chief Executive Officer , Diagnostic Solutions Segment , Order Intake , Investor Relations , States Toll Free , Constant Currency Revenue , Adjusted Operating Profit , Adjusted Operating Profit Margin , Adjusted Net Profit , Adjusted Diluted , Capital Employed , Net Cash , Free Cash Flow , Marketing Expenses , Administrative Expenses , Constant Currency , Operating Profit , Income Taxes , Operating Activities , Net Debt , Intangible Assets , Net Profit , Stevanato , Group , Reports , First , Quarter , 023 , Financial , Results ,